AnTolRx
Vincent Stanton is an entrepreneur and consultant who has worked for a variety of diagnostics and therapeutics clients on drug development and personalized medicine projects. Vincent was formerly Senior Vice President of Research at Variagenics, an early genomics firm where he helped guide research from startup through IPO, including several major shifts in scientific and business strategy. After medical school, Vincent completed a pathology residency at Brigham and Women’s Hospital, followed by postdoctoral training at Dana-Farber Cancer Institute and MIT.
This person is not in the org chart
This person is not in any teams
This person is not in any offices
AnTolRx
AnTolRx’s vision is to build a platform that selectively targets pathogenic immune cells providing a unique tolerogenic signal to induce an anti-inflammatory phenotype and better treat diseases.